Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 19 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2010Rationale and design of the Endurant Stent Graft Natural Selection Global Postmarket Registry (ENGAGE): interim analysis at 30 days of the first 180 patients enrolledBockler, D.; Fitridge, R.; Wolf, Y.; Hayes, P.; Silveira, P.; Numan, F.; Riambau, V.
2015Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non–small-cell lung cancerRamalingam, S.S.; Shtivelband, M.; Soo, R.A.; Barrios, C.H.; Makhson, A.; Segalla, J.G.; Pittman, K.B.; Kolman, P.; Pereira, J.R.; Srkalovic, G.; Belani, C.P.; Axelrod, R.; Owonikoko, T.K.; Qin, Q.; Qian, J.; McKeegan, E.M.; Devanarayan, V.; McKee, M.D.; Ricker, J.L.; Carlson, D.M.; et al.
2013Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, mutlicentre, randomised phase 3 studyBuikhuisen, W.; Burgers, J.; Vincent, A.; Korse, C.; van Klaveren, R.; Schramel, F.; Pavlakis, N.; Nowak, A.; Custers, F.; Schouwink, J.; Gans, S.; Groen, H.; Strankinga, W.; Baas, P.
2013Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialVermorken, J.; Stohlmacher-Williams, J.; Davidenko, I.; Licitra, L.; Winquist, E.; Villanueva, C.; Foa, P.; Rottey, S.; SkladowskI, K.; Tahara, M.; Pai, V.; Faivre, S.; Blajman, C.; Forastiere, A.; Stein, B.; Oliner, K.; Pan, Z.; Bach, B.
2015A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinomaPal, S.; Azad, A.; Bhatia, S.; Drabkin, H.; Costello, B.; Sarantopoulos, J.; Kanesvaran, R.; Lauer, R.; Starodub, A.; Hauke, R.; Sweeney, C.; Hahn, N.; Sonpavde, G.; Richey, S.; Breen, T.; Kremmidiotis, G.; Leske, A.; Doolin, E.; Bibby, D.; Simpson, J.; et al.
2012Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trialBurmeister, B.; Henderson, M.; Ainslie, J.; Fisher, R.; Di Iulio, J.; Smithers, B.; Hong, A.; Shannon, K.; Scolyer, R.; Carruthers, S.; Coventry, B.; Babington, S.; Duprat, J.; Hoekstra, H.; Thompson, J.
2011Apixaban versus Warfarin in patients with atrial fibrillationGranger, C.; Alexander, J.; McMurray, J.; Lopes, R.; Hylek, E.; Hanna, M.; Al-Khalidi, H.; Ansell, J.; Avezum, A.; Atar, D.; Bahit, M.; Diaz, R.; Easton, J.; Ezekowitz, J.; Garcia, D.; Geraldes, M.; Gersh, B.; Golitsyn, S.; Goto, S.; Hermosillo, A.; et al.
2010Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.
2010Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX studyTebbutt, N.; Wilson, K.; Gebski, V.; Cummins, M.; Zannino, D.; van Hazel, G.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S.; Forgeson, G.; Cunningham, D.; Saunders, M.; Stockler, M.; Chua, Y.; Zalcberg, J.; Simes, R.; Price, T.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.